F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 25, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 15, 2017

Conditions
Merkel Cell Carcinoma
Interventions
DRUG

Arm A: F16IL2 in combination with paclitaxel

"Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m\^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."

DRUG

Arm B: Paclitaxel

"Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m\^2 on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."

Trial Locations (8)

Unknown

Medical University Hospital, Graz

Herlev- University Hospital, Herlev

Saint-Louis- Hospital, Paris

Charité- Medical University Hospital, Berlin

Universitätsklinik Essen, Essen

Eberhard-Karls- University Hospital, Tübingen

ICMiD- University Hospital, Barcelona

Nottingham Trent- University Hospital, Nottingham

Sponsors
All Listed Sponsors
collaborator

Immatics Biotechnologies GmbH

INDUSTRY

lead

Philogen S.p.A.

INDUSTRY

NCT02054884 - F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma | Biotech Hunter | Biotech Hunter